Progress of OX40 and its ligand in lymphoma immunotherapy

VernacularTitle:OX40及其配体在淋巴瘤免疫治疗中的研究进展
Author: Mengdi LIU ¹ ; Wei SANG ; Kailin XU
Author Information

1. 徐州医科大学附属医院血液科徐州医科大学血液病研究所 221000
Keywords: Lymphoma; OX40; OX40 ligand; Immunotherapy
From: Journal of Leukemia & Lymphoma 2019;28(6):371-375
CountryChina
Language:Chinese
Abstract: OX40 is a member of the tumor necrosis factor receptor (TNFR) superfamily. In the immune response of the body, OX40 and the OX40 ligand (OX40/OX40L) on the antigen-presenting cell membrane are important co-stimulatory molecules, which can promote the proliferation of T cells. And OX40 also has the dual role of activating and enhancing the T cell immune response. OX40/OX40L is an important target for tumor immunotherapy, and clinical studies of several OX40 agonists are currently underway. This article reviews the immunoregulatory mechanisms of OX40/OX40L and its research progress in lymphoma immunotherapy.